Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation

Molecular Cancer Therapeutics

Volumn 4, Issue 2, 2005, Pages 207-216

  Katiyar, Santosh K ^a,b   Roy, Anshu M ^a   Baliga, Manjeshwar S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 3; CYTOCHROME C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SERINE; SILIBININ; SILYMARIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME RELEASE; FLOW CYTOMETRY; KERATINOCYTE; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKIN FIBROBLAST; STAINING; WILD TYPE;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASES; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; CYTOCHROMES C; DOWN-REGULATION; FIBROBLASTS; KERATINOCYTES; MICE; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SILYMARIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 14844320063     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wagner H, Horhammer L, Munster R. Chemistry of silymarin (silibinin), the active principle of the fruits of Silybum marianum (L.) Gaertn. (Carduus marianus L.). Arzneimittelforschung 1968;18:688-96.
2. Katiyar SK. Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects. Int J Oncol 2005;26: 169-76.
3. Chatterjee ML, Katiyar SK, Mohan RR, Agarwal R. Flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in SENCAR mouse skin tumorigenesis model. Cancer Res 1999;59:622-32.
4. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997;89:556-66.
5. Katiyar SK. Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J Oncol 2002;21:1213-22.
6. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
7. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995;11:199-210.
8. Mass P, Hoffmann K, Gambichler T, Altmeyer P, Mannherz HG. Premature keratinocyte death and expression of marker proteins of apoptosis in human skin after UVB exposure. Arch Dermatol Res 2003;295:71-9.
9. Ellis RE, Yuan J, Horvitz HR. Mechanisms and functions of cell death. Annu Rev Cell Biol 1991;7:663-98.
10. Wyllie AH, Kerr FR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-70.
11. Raff MC. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 1992;356:397-400.
12. Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis 2004;25:1459-65.
13. Yoo HG, Jung SN, Hwang YS, et al. Involvement of NF-κB and caspases in silibinin-induced apoptosis of endothelial cells. Int J Mol Med 2004;13:81-6.
14. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science (Washington DC) 1997;275:1129-32.
15. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Washington DC) 1997;275:1132-36.
16. Reed JC. Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995;7:541-6.
17. Colburn NH, Former BF, Nelson KA, Yuspa SH. Tumor promoter induces anchorage independence irreversibly. Nature (Lond) 1979;281: 589-91.
18. Colburn NH, Smith BM, Wendel EJ, Dowjat WK, Shimada T. Transfer of pro gene transfection of tumor promoter-sensitive phenotype to promotion-insensitive JB6 cells. Cancer Res 1988;48:1195-200.
19. He Z, Ma W-Y, Hashimoto T, Bode AM, Yang CS, Dong Z. Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res 2003;63:4396-401.
20. Huang C, Ma W, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999;20:237-42.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
22. Mittal A, Pate MS, Wylie RC, Tollefsbol TO, Katiyar SK. EGCG downregulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. Int J Oncol 2004;24:703-10.
23. Vayalil PK, Elmets CA, Katiyar SK. Treatment of green tea polyphenols in hydrophilic cream prevents UVB-induced oxidation of lipids and proteins, depletion of antioxidant enzymes and phosphorylation of MAPK proteins in SKH-1 hairless mouse skin. Carcinogenesis 2003;24:927-36.
24. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
25. Dumaz N, Meek DW. Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 1999;18:7002-10.
26. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
27. Larsen CJ. [The BCL2 gene, prototype of a gene family that controls programmed cell death (apoptosis)] in French. Ann Genet 1994;37: 121-34.
28. Zhan Q, Fan S, Bae I, et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994;9:3743-51.
29. Gupta S, Hastak K, Afaq F, Ahmad N, Mukhtar H. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor κB and induction of apoptosis. Oncogene 2004;23: 2507-22.
30. Bhatia N, Zhao J, Wolf DM, Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett 1999;147:77-84.
31. Wright SC, Zhong J, Larrick JW. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 1994;8:654-60.
32. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
33. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121-29.
34. Barry MA, Behnke CA, Eastmann A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins, and hyperthermia. Biochem Pharmacol 1990;40:2353-62.
35. Symonds H, Krall L, Remington L, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78: 703-11.
36. Lowe SW, Jacks T, Housman DE, Ruley HE. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci U S A 1994;91:2026-30.
37. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992;356:215-21.
38. Hollstein M, Rice K, Greenbalt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-5.
39. Komarova EA, Chernov MV, Franks R, et al. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 1997;16:1391-400.
40. Tibbetts RS, Brumbaugh KM, Williams JM, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999;13: 152-7.
41. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997;91: 325-34.
42. Venkatachalam S, Shi YP, Jones SN, et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998;17:4657-67.
43. Kaina B. DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. Biochem Pharmacol 2003;66:1547-54.
44. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997;385: 637-40.
45. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci U S A 1997;94:2345-9.
46. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001;13: 332-7.
47. Donovan M, Cotter TG. Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death. Biochim Biophys Acta 2004;1644:133-47.